Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.44 |
| ▸ | GAA | P10253 | 5/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.42 |
| ▸ | BLM | P54132 | 3/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | DAO | P14920 | 1/20 | 0.42 |
| ▸ | AURKA | O14965 | 1/20 | 0.42 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.42 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.38 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | DRD1 | P21728 | 1/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | PARP1 | P09874 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1536393 | 0.80 | PARP1 (0.52) | KDM4EKMT2ABLMALDH1A1TDP1 | |
| SCHEMBL8143588 | 0.72 | — | — | |
| SCHEMBL12649434 | 0.72 | — | — | |
| SCHEMBL215300 | 0.72 | — | — | |
| SCHEMBL27261099 | 0.72 | KDM4E (0.44) | KDM4EGAAKMT2ABLML3MBTL1 | |
| Water SCHEMBL15757647 | 0.71 | L3MBTL1 (0.54) | KDM4EGAAKMT2ABLML3MBTL1 | |
| SCHEMBL4654255 | 0.70 | DRD1 (0.48) | KDM4EGAAKMT2AL3MBTL1POLB | |
| SCHEMBL28139594 | 0.69 | KDM4E (0.44) | KDM4EGAAKMT2ABLML3MBTL1 | |
| SCHEMBL10587082 | 0.68 | DAO (0.46) | KDM4EGAAKMT2ABLML3MBTL1 | |
| SCHEMBL29848758 | 0.68 | KDM4E (0.43) | KDM4EGAAKMT2ABLML3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4634170-A1 | IMIDAZO[4,5-B]PYRIDINE DERIVATIVES AS PCSK9 INHIBITORS AND METHODS OF USE THEREOF | AstraZeneca AB (SE) | 2025-10-22 | — | — | EP | disclosed |
| EP-4590397-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | Astrazeneca AB (SE) | 2025-07-30 | — | — | EP | disclosed |
| US-20240228469-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2024-07-11 | — | — | US | disclosed |
| WO-2024126773-A1 | IMIDAZO[4,5-B]PYRIDINE DERIVATIVES AS PCSK9 INHIBITORS AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2024-06-20 | — | — | WO | disclosed |
| WO-2024062090-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2024-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228469-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | PCSK9, PCSK7, PCSK6 | KDM4E 3520/4885GAA 920/4885KMT2A 3367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.